PT - JOURNAL ARTICLE AU - Walter, Katharine S. AU - dos Santos, Paulo César Pereira AU - Gonçalves, Thais Oliveira AU - da Silva, Brunna Oliveira AU - da Silva Santos, Andrea AU - de Cássia Leite, Alessandra AU - da Silva, Alessandra Moura AU - Figueira Moreira, Flora Martinez AU - de Oliveira, Roberto Dias AU - Lemos, Everton Ferreira AU - Cunha, Eunice AU - Liu, Yiran E. AU - Ko, Albert AU - Colijn, Caroline AU - Cohen, Ted AU - Mathema, Barun AU - Croda, Julio AU - Andrews, Jason R. TI - Genomic evidence for prisons as amplifiers of community tuberculosis epidemics AID - 10.1101/2021.06.22.21259360 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.22.21259360 4099 - http://medrxiv.org/content/early/2021/06/24/2021.06.22.21259360.short 4100 - http://medrxiv.org/content/early/2021/06/24/2021.06.22.21259360.full AB - Prisons are high-incidence settings for tuberculosis around the world, yet the contribution of spillover from prisons in driving community epidemics has not been quantified. We whole genome sequenced 1,152 M. tuberculosis isolates from participants diagnosed with tuberculosis within prisons and in the community in Mato Grosso do Sul, Brazil from 2014 to 2019. By integrating timed phylogenies and detailed location data, we reconstructed probabilistic transmission histories. M. tuberculosis sequences from incarcerated and non-incarcerated people were closely phylogenetically related. We found that 57% of recent community-wide tuberculosis cases were attributable to transmission from individuals with an incarceration history, 2.6% of the population. Further, we find genomic evidence that the prison system disseminates M. tuberculosis genotypes through frequent transfers across the state. This population-wide genomic transmission reconstruction framework can be applied to identify key environments amplifying infectious disease transmission to prioritize public health interventions.Teaser Prison spillover plays an outsized role in community tuberculosis transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institutes of Health grant R01AI130058 (JRA) Brazilian National Council for Scientific and Technological Development grant 404237/2012-6 (JC)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written consent, and this study was conducted with the approval of the Research Ethics Committee from the Federal University of Grande Dourados, Federal University of Mato Grosso do Sul and National Research Ethics Committee (CONEP) (CAAE 37237814.4.0000.5160, 2676613.3.1001.5160, and 26620619.6.0000.0021) and Stanford University Institutional Review Board (IRB-40285).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is available on the Sequence Read Archive (SRA), in BioProject PRJNA671770.